Introduction

Some diseases are rare. Others are complicated. AARS2 Deficiency is both.

It’s a condition that affects one of the most essential parts of our biology, our mitochondria, often called the “powerhouses” of our cells. But what makes AARS2 Deficiency especially difficult is that even though we know where the problem starts, we still don’t fully understand how or why it leads to such a wide range of symptoms.

It’s a genetic disorder. It’s a mitochondrial disease. It’s linked to protein production. But none of these labels fully explain it and that’s exactly what makes AARS2 such a scientific mystery.

At Curetopia, we’re committed to unlocking that mystery. And here’s what makes this disease so uniquely puzzling and why it’s time to approach it differently.

What Exactly Is AARS2 Deficiency?

AARS2 Deficiency is a rare genetic disorder caused by changes in a gene called AARS2, short for Alanyl-tRNA synthetase 2. This gene plays a crucial role in helping cells build proteins—specifically in the mitochondria, the part of the cell responsible for producing energy.

When this gene isn’t working properly, protein production in the mitochondria becomes disrupted. That may sound small, but the effects can be life-altering.

Because mitochondria fuel nearly every function in the body, problems with mitochondrial protein synthesis can show up in many different ways often making diagnosis extremely difficult. Some patients may experience muscle weakness, heart failure, or brain disorders like leukodystrophy, while others might show entirely different symptoms.

To make things even more complicated, some people with AARS2 mutations may not develop symptoms until later in life, while others show signs from birth. There’s still no clear way to predict who will be affected, how severely, or why.

That’s part of the challenge: the science behind the disease is deeply complex, and every patient’s story looks a little different.

The Mitochondria Puzzle: What’s Going Wrong?

To understand AARS2 Deficiency, we need to understand what’s happening inside the mitochondria, the tiny structures in our cells responsible for producing the energy we need to survive.

Mitochondria have their own system for making proteins, separate from the rest of the cell. That system relies on enzymes like AARS2 to help build those proteins correctly. Think of AARS2 as part of a high-precision assembly line. When that one part breaks down, the entire system starts to malfunction.

When AARS2 isn't working properly, mitochondria struggle to produce proteins they need to generate energy. This disruption can affect any organ or tissue that relies heavily on energy—like the heart, brain, muscles, and nervous system. That’s why the symptoms of AARS2 Deficiency can look so different from person to person.

What makes things even more puzzling is that researchers still don’t fully understand why the same genetic mutation can cause such a wide range of symptoms. Why do some people develop heart problems, while others face neurological decline? Why do some patients get worse quickly, while others remain stable for years?

There may be other genetic or environmental factors involved, what scientists call disease modifiers but we’re still in the early stages of figuring those out. For now, AARS2 remains a puzzle where we know the pieces exist, we just don’t know how they all fit together yet.

Why Traditional Research Isn’t Enough

One of the biggest reasons progress on AARS2 Deficiency has been so slow is because traditional research methods weren’t built to handle diseases like this.

Most scientific research follows a long, structured process starting with lab models, moving to animal studies, and then eventually reaching large-scale clinical trials. But for ultra-rare conditions like AARS2 Deficiency, this system doesn’t work well.

There simply aren’t enough patients to run large trials. Research funding usually goes to more common diseases. And lab models often fail to reflect how the disease actually behaves in the human body. As a result, promising ideas get stuck in early stages or worse, never even get explored.

On top of that, most traditional research is controlled by a few institutions and funders. That means decisions about which diseases get attention are often based on market potential, not medical urgency. AARS2 Deficiency falls through the cracks not because it’s untreatable, but because it doesn’t fit the system.

That’s why new research models are needed—ones that are faster, more flexible, and more inclusive. This is where community-driven science, open collaboration, and decentralized clinical research can make a real difference.

When patients, scientists, and supporters come together to shape the direction of research, it becomes possible to study conditions like AARS2 in smarter, more patient-centered ways.

A New Way Forward: What It’ll Take to Solve AARS2

Solving AARS2 Deficiency won’t come from doing more of the same. It will take fresh thinking, new tools, and a more open, collaborative way of doing science.

Traditional approaches to rare disease research are often too slow, too centralized, and too disconnected from the people most affected. That’s why more researchers and patient communities are turning toward decentralized, community-led models. When scientists, patients, developers, and supporters work side by side, research becomes faster, more focused, and more meaningful.

Rather than waiting years for large clinical trials that may never happen, researchers can explore N-of-1 trials, where individual patients are studied in depth. Instead of relying on slow, institutional funding processes, communities can pool resources and decide collectively which projects deserve support. And rather than keeping data locked away, open collaboration allows progress to build in real time, across teams, borders, and disciplines.

That’s the model we’re building at Curetopia.

By bringing together researchers, patient families, and contributors in one shared ecosystem, Curetopia is rethinking how rare disease research happens from discovery to design to funding. Our work with AARS2 Deficiency reflects this shift. We’re not just supporting research, we’re co-creating it, with the people who care most about the outcomes.

From identifying repurposed drug candidates using high-throughput yeast screening to developing patient-centered trial models, we’re focused on approaches that can move faster, cost less, and reflect real-world needs not just institutional priorities.

There’s still a lot to uncover about AARS2. But by working together, openly and differently, we believe the path forward is clearer than it’s ever been.

And it starts with a community that refuses to wait.

‍